Xhance Pvt
Manufacturing · United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.xhance.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Xhance Pvt
Optinose is a biopharmaceutical company that specializes in developing innovative treatments for chronic sinusitis, particularly with their prescription product, XHANCE. XHANCE is specifically designed to treat chronic rhinosinusitis in adults and is the first FDA-approved nasal spray of its kind. The company aims to provide accessible treatment options through third-party telemedicine partnerships, making consultations and prescriptions easily available online. Targeting adults suffering from chronic nasal issues, Optinose prioritizes patient education and offers savings opportunities for insured clients.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Xhance Pvt your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Xhance Pvt, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Xhance Pvt recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check if Xhance Pvt has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Xhance Pvt
Funding: Get notified immidiatlly once Xhance Pvt has new funding data
Check out if Xhance Pvt is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Xhance Pvt had a recent Job posting/layoffs
Product Launch: Get notified when Xhance Pvt launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Xhance Pvt is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Xhance Pvt is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Xhance Pvt.
Xhance Pvt Tech Stack
A closer look at the technologies used by Xhance Pvt
Xhance Pvt News & Media
Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion
YARDLEY, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the submission of its supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) to request approval of XHANCE as a treatment for chronic rhinosinusitis. XHANCE® (fluticasone propionate) nasal spray is a drug device combination product combining an anti-inflammatory drug witOptinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program
Company previously announced positive top-line results from both ReOpen1 and ReOpen2, the landmark trials evaluating XHANCE as a treatment for chronic sinusitisOptinose Announces Peer-Reviewed Publication of the Fourth Major XHANCE Registration Trial
YARDLEY, Pa., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that results of the Phase 3 EXHANCE-3 trial were published in the peer-reviewed journal Rhinology1, the official journal of the International Rhinologic Society. Optinose to Highlight Data at Two Upcoming Scientific Meetings
YARDLEY, Pa., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that data concerning its product XHANCE® will be presented at the American Rhinologic Society (ARS) 64th Annual Meeting in Atlanta, Georgia, October 5-6, 2018, and the American Academy Of Otolaryngology-Head and Neck Surgery Annual Meeting in Atlanta, Georgia, October 7-10, 2018. Abstracts are available
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Xhance Pvt
Sign Up For FreeTo access detailed company insights
Optinose is a biopharmaceutical company that specializes in developing innovative treatments for chronic sinusitis, particularly with their prescription product, XHANCE. XHANCE is specifically designed to treat chronic rhinosinusitis in adults and is the first FDA-approved nasal spray of its kind. The company aims to provide accessible treatment op... Read More
